

### AMENDMENTS TO THE CLAIMS

1 (Currently amended). A method of treatment of

(a) a patient in need of modulation of body mass or modulation of increase in body mass, and/or in need of modulation of plasma insulin, plasma glucose, plasma triglycerides and/or plasma cholesterol,

(b) a patient in need of an antitumour agent or an antiinflammatory agent, or in need of modulation in lipid or eicosanoid status, or

(c) a patient in need of modulation of PPAR activity, comprising administering to the patient an effective amount of a compound comprising perfluorooctanoic acid or a salt or an ester thereof, perfluorosuberic acid, perfluoroheptanoic acid, perfluorohexanoic acid, perfluoropentanoic acid, perfluorobutanoic acid or perfluoropropionic acid or a salt or an ester any thereof , or perfluorooctane.

2 (Canceled).

3 (Previously presented). The method of claim 1

wherein the patient is overweight or obese and/or has diabetes, hyperlipidaemia, atherosclerosis, coronary heart disease, stroke, obstructive sleep apnoea, arthritis and/or reduced fertility, or is at risk of developing such a condition.

4 (Canceled).

5 (Canceled).

6 (Currently amended). A method of manufacturing a medicament for treating ~~a patient as defined in claim 1~~

(a) a patient in need of modulation of body mass or modulation of increase in body mass, and/or in need of modulation of plasma insulin, plasma glucose, plasma triglycerides and/or plasma cholesterol,

(b) a patient in need of an antitumour agent or an antiinflammatory agent, or in need of modulation in lipid or eicosanoid status or function, or of modulation of a lipid metabolizing or binding entity activity, or

(c) a patient in need of modulation of PPAR activity, comprising

using a compound as defined in claim 1.

7 (Currently amended). The method of claim 1 [4]  
wherein the patient is in need of an increase in PPAR activity and the compound is a PPAR  
agonist.

8 (Previously presented). The method of claim 7  
wherein the PPAR is PPAR $\alpha$  or PPAR $\gamma$ .

9 (Canceled).

10 (Previously presented). The method of claim 1  
wherein the patient is in need of reduction of body mass or prevention of increase in body  
mass, and/or in need of reduction of plasma insulin, plasma glucose, plasma triglycerides and/or  
plasma cholesterol.

11 (Previously presented). The method of claim 6  
wherein the medicament is for the treatment of a patient who is overweight or obese and/or  
has diabetes, hyperlipidaemia, atherosclerosis, coronary heart disease, stroke, obstructive sleep  
apnoea, arthritis and/or reduced fertility, or is at risk of developing such a condition.

12 (Canceled).

13 (Previously presented). The method of claim 1  
wherein the compound is or comprises a perfluorooctanoic acid, or is more than 75% linear  
perfluorooctanoic acid or a salt or ester thereof.

14 (Previously presented). The method of claim 1  
wherein the compound is or comprises a perfluoroheptanoic acid or salt or ester thereof.

15 (Previously presented). The method of claim 1  
wherein the compound is a perfluoropentanoic acid or salt or ester thereof.

16 (Canceled).

17 (Currently amended). A screening method for identifying a drug-like compound or lead  
compound for the development of a drug-like compound comprising  
exposing a mammal to a compound as defined in claim 1 or derivative thereof, and  
measuring at least one of the plasma insulin, glucose, cholesterol, triglyceride, bodyweight,  
and lipid or eicosanoid status or function of the mammal.

18 (Previously presented). The method of claim 17, further comprising  
the step of selecting a compound on exposure to which the plasma insulin, glucose,

cholesterol and/or triglyceride level of the mammal is changed or reduced, and/or bodyweight or bodyweight increase of the mammal is changed or reduced.

19 (Previously presented). A screening method for identifying a drug-like compound or lead compound for the development of a drug-like compound comprising  
exposing a compound as defined in claim 1 or derivative thereof to a PPAR polypeptide,  
and  
measuring at least one of binding of the compound to the PPAR polypeptide or the change in the activity of the PPAR polypeptide.

20 (Previously presented). A screening method for identifying a drug-like compound or lead compound for the development of a drug-like compound comprising  
exposing a compound as defined in claim 1 or derivative thereof to a lipid metabolising or binding entity, and  
measuring at least one of the binding of the compound to the lipid metabolising or binding entity or the change in the activity of the lipid metabolising or binding entity.

21 (Previously presented). A screening method for identifying a drug-like compound or lead compound for the development of a drug-like compound comprising  
exposing a cell to a compound as defined in claim 1, and  
measuring at least one of the phenotype and the eicosanoid biosynthesis of the cell.

22 (Previously presented). The method of claim 21, further comprising  
the step of selecting a compound on exposure to which at least one of the phenotype of the cell or the eicosanoid biosynthesis of the cell is changed.

23 (Currently amended). The method of ~~of~~ claim 1  
wherein the compound is identified or identifiable by the screening method of claim 17.

24 (Canceled).

25 (Previously presented). A food product comprising  
a foodstuff, and  
a compound as defined in claim 1.

26 (Previously presented). A kit of parts of screening system comprising  
a library of compounds each as defined in claim 1, and  
a PPAR polypeptide or polynucleotide encoding a PPAR polypeptide, and/or a test

mammal.

27 (Previously presented). A kit of parts of screening system comprising a library of compounds each as defined in claim 1, and at least one of a lipid metabolising or binding entity or a polynucleotide encoding a lipid metabolising or binding entity.

28 (Canceled).

29 (Currently amended). A method as in claim [4] 1 wherein the PPAR activity is PPAR $\alpha$  activity.

30 (Canceled).

31 (Currently amended). A method as in claim ~~30~~ 6 wherein the PPAR activity is PPAR $\alpha$  activity.

32 (Currently amended). A method as in claim ~~30~~ 6 wherein the medicament is for the treatment of a patient in need of an increase in PPAR activity and the compound is a PPAR agonist.

33 (Canceled).

34 (Previously presented). The method of claim 1 wherein the compound is identified or identifiable by the screening method of claim 19.

35 (Previously presented). The method of claim 1 wherein the compound is identified or identifiable by the screening method of claim 20.

36 (Previously presented). The method of claim 1 wherein the compound is identified or identifiable by the screening method of claim 21.

37 (Previously presented). A food product as in claim 25 wherein the foodstuff is not laboratory rodent feed.